Curis (CRIS) : Traders are bullish on Curis (CRIS) as it has outperformed the S&P 500 by a wide margin of 19.18% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 8.61%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 9.19% in the last 1 week, and is up 16.76% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 13.71% and the 50-Day Moving Average is 17.1%.The 200 Day SMA reached 8.87% Curis, Inc. is up 27.85% in the last 3-month period. Year-to-Date the stock performance stands at -30.58%.
Curis (CRIS) : The most positive equity analysts on Curis (CRIS) expects the shares to touch $7, whereas, the least positive believes that the stock will trade at $3 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $5.33 with an expected fluctuation of $2.08 from the mean.
For the current week, the company shares have a recommendation consensus of Buy. Curis (NASDAQ:CRIS): The stock opened at $1.91 and touched an intraday high of $2.03 on Friday. During the day, the stock corrected to an intraday low of $1.85, however, the bulls stepped in and pushed the price higher to close in the green at $2.02 with a gain of 6.88% for the day. The total traded volume for the day was 1,045,682. The stock had closed at $2.02 in the previous trading session.
Curis, Inc. (Curis) is a biotechnology company. The Company is engaged in the development and commercialization drug candidates for the treatment of human cancers. The Companys drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Curis product pipeline also includes CUDC-427, an orally available, small molecule antagonist of inhibitor of apoptosis (IAP) proteins. CUDC-907 is in Phase I clinical trial stage for the treatment of advanced lymphomas and multiple myeloma, and human epidermal growth factor receptor 2 (HER 2-), estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+) breast cancer and NUT midline carcinoma. CUDC-427 is in Phase I clinical trial stage for the treatment of advanced solid tumor and lymphomas. The Companys PD-L1 antagonist and IRAK4 Inhibitor drug candidates are in preclinical stage of development.